Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners

December 09, 2022

The addition of cemiplimab and REGN3767 to paclitaxel improved pathologic complete response vs paclitaxel alone in patients with triple-negative and hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 2 I-SPY2 trial.

December 02, 2022

Stephen V. Liu, MD, highlights the advantages of antibody-drug conjugates in lung cancer treatment, the current landscape of antibody-drug conjugate development, and several questions and considerations for continued investigation.

November 29, 2022

Stephen V. Liu, MD, discusses efforts to develop atezolizumab-based combination therapies for patients with small cell lung cancer.

November 18, 2022

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, have recognized 4 gastrointestinal physician-scientists and a prominent patient advocate, naming them as 2022 Luminary Awards in GI Cancers.

October 13, 2022

John L. Marshall, MD, provides an overview of esophageal squamous cell carcinoma and discusses several key updates to the treatment landscape, including putting data in the context of the treatment algorithm.

October 11, 2022

Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.

October 05, 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

August 19, 2022

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

June 30, 2022

The addition of durvalumab to gemcitabine and cisplatin demonstrated an improvement in overall survival vs gemcitabine and cisplatin plus placebo as frontline therapy in patients with advanced biliary tract cancer, regardless of primary tumor location.

June 15, 2022

Geoffrey T. Gibney, MD, discusses current treatment options for patients with melanoma, clinical trials that have explored different agents and combinations, and developing treatment options in uveal melanoma.

June 07, 2022

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

March 31, 2022

John L. Marshall, MD, discusses potential next steps with research in bile duct cancer.

February 24, 2022

“I don’t intend to rest on any laurels as thereis still much more to be done.”

December 08, 2021

Safety and efficacy data from a pooled pooled analysis confirm that patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer can be treated with palbociclib plus endocrine therapy.

October 25, 2021

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

October 23, 2021

The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.

October 20, 2021

John Marshall, MD, discusses the results of the DESTINY-Gastric02 trial with trastuzumab deruxtecan in patients with HER2-positive gastric/GEJ cancer, the importance of molecular profiling, and future considerations for the antibody-drug conjugate.

October 15, 2021

John L. Marshall, MD, discusses key findings from the phase 2 DESTINY-Gastric02 trial examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive gastric cancer.

September 14, 2021

John L. Marshall, MD, discusses factors to consider in the third-line treatment setting for patients with colorectal cancer.

June 22, 2021

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.